Lv3
360 积分 2025-10-14 加入
Intraorbital rituximab to treat orbital inflammation in a patient with active neoplasia
7天前
已关闭
Teprotumumab N01 for thyroid eye disease in China: clinical outcomes and quantitative MRI correlations
7天前
已完结
Long-Term Impact of Thyroid Eye Disease on Quality of Life: Insights From a Retrospective Cohort Study
8天前
已完结
A comparative study of the characteristics and prognosis of orbital myositis versus thyroid-associated orbitopathy
8天前
已关闭
Fluoropolymer‐Mediated Delivery of a Dual TSHR/IGF1R‐Targeting CRISPR‐Cas9 System for Localized Therapy in Thyroid‐Associated Ophthalmopathy
16天前
已完结
Longitudinal Glycemic Outcomes in Patients With Thyroid Eye Disease Treated With Teprotumumab
16天前
已关闭
Proptosis Regression After Teprotumumab Treatment for Thyroid Eye Disease
23天前
已完结
Teprotumumab Use in Thyroid Eye Disease: Clinical Outcomes in the United Arab Emirates– a First Regional Case Series
1个月前
已完结
Teprotumumab treatment for dysthyroid optic neuropathy
1个月前
已完结
Beyond the Eyes: Is Teprotumumab Effective for Thyroid Dermopathy?
1个月前
已完结
皖公网安备34019202002308
